TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33766702
Drug: Individualized nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized nutritional counseling every 2 weeks during therapy
Study: 32631586
Drug: estradiol 1
Normalized name: estradiol 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: estradiol 1 mg combined with drospirenone 2 mg
Study: 33836635
Drug: Azacitidine (AZA)
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine (AZA) and histone deacetylase inhibitors (HDACi) combination
Study: 32930040
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) for chronic fatigue syndrome
Study: 33234323
Drug: Visuomotor therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visuomotor therapy (active)
Study: 35686576
Drug: Interdisciplinary graded
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interdisciplinary graded exposure treatment (GET Living)
Study: 32989170
Drug: Combined Oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Oral Contraceptives (COC) (Triphasil or Nordette)
Study: 33481828
Drug: Prism adaptation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prism adaptation treatment (PAT)
Study: 33481828
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (active control)
Study: 36054480
Drug: Sacubitril/valsartan (97
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan (97 mg of sacubitril and 103 mg of valsartan twice daily)
Study: 36321459
Drug: Ramipril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (5 mg twice daily)
Study: 35543939
Drug: Flunarizine hydrochloride
Normalized name: flunarizine hydrochloride
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine hydrochloride capsule, 10 mg a day for 4 weeks
Study: 35947864
Drug: Brief Solution
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Solution Focused Therapy (BSFT), 5 sessions over 3 months
Study: 32933504
Drug: Febuxostat 40
Normalized name: febuxostat 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat 40 mg once daily
Study: 32933504
Drug: Terminalia bellerica
Normalized name: Terminalia bellirica fruit extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terminalia bellerica (TBE) 500 mg twice daily
Study: 32933504
Drug: Terminalia bellerica
Normalized name: Terminalia bellirica fruit extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terminalia bellerica (TBE) 1000 mg twice daily
Study: 39452487
Drug: PCSK9 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCSK9 inhibitors
Study: 35417958
Drug: Iron therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron therapy (1000 mg ferric carboxymaltose in 100 mL saline, infused slowly over 15 min 7 days before surgery)
Study: 35417958
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 mL saline, infused slowly over 15 min 7 days before surgery)
Study: 34579112
Drug: Inulin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inulin (10 g/day)
Study: 34579112
Drug: Placebo (maltodextrin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin, 10 g/day)
Study: 36065810
Drug: Low-dose nelonemdaz
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose nelonemdaz (2750 mg)
Study: 36065810
Drug: High-dose nelonemdaz
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose nelonemdaz (5250 mg)
Study: 34391264
Drug: Knitting program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knitting program (8-week duration) with bi-weekly 20-min group sessions and daily 20-min home sessions
Study: 35507508
Drug: CoVLP+AS03 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoVLP+AS03 vaccine
Study: 36100263
Drug: Extended duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended duration thromboprophylaxis using daily subcutaneous tinzaparin at 4500 IU for 56 days postoperatively
Study: 36100263
Drug: Extended duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended duration thromboprophylaxis using daily subcutaneous tinzaparin at 4500 IU
Study: 33230290
Drug: No-treatment delivered
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment delivered by VEx
Study: 33230290
Drug: No-treatment delivered
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment delivered by text-only control
Study: 33230290
Drug: Expectancy manipulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectancy manipulation (placebo or no-treatment)
Study: 33230290
Drug: VEx regardless
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEx regardless of treatment
Study: 35564596
Drug: Antenatal corticosteroids
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal corticosteroids (two doses of IM dexamethasone 12 mg, 12 hours apart, 24 hours prior to surgery)
Study: 32086819
Drug: Eculizumab (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab (single infusion)
Study: 34807716
Drug: mRNA-1273 vaccine
Normalized name: SARS-CoV-2 mRNA-1273 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 vaccine (third dose)
Study: 36343880
Drug: Group-based Family-Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based Family-Based Treatment (FBT)
Study: 36343880
Drug: Guided self-help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided self-help Family-Based Treatment (gshFBT)
Study: 32371430
Drug: FKB327 or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: FKB327 or RP (with treatment switching)
Study: 35552824
Drug: Oxabact (lyophilized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxabact (lyophilized O. formigenes formulation), administered orally, twice daily for 52 weeks.
Study: 35552824
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered orally, twice daily for 52 weeks.
Study: 35350970
Drug: START-Play physical
Normalized name: Star Anise Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: START-Play physical therapy intervention
Study: 32379483
Drug: High-intensity ultrasonically
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity ultrasonically nebulized distilled water (UNDW) inhalations (1.6 ml/min)
Study: 32379483
Drug: Low-intensity UNDW
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity UNDW inhalations (0.5 ml/min)
Study: 32379483
Drug: Control, 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control, 0.9% saline inhalations (1.6 ml/min)
Study: 32519005
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline (HS) - 5 ml/kg body weight of 7.3% NaCl over 60 min
Study: 32423706
Drug: Antidepressant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant therapy (combined with desmopressin if needed)
Study: 32423706
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment including desmopressin
Study: 34378862
Drug: Chlorhexidine gel
Normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gel 1% applied inside the implant hex
Study: 32059705
Drug: De-escalated primary
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De-escalated primary radiotherapy (60 Gy) ± concomitant chemotherapy
Study: 35870710
Drug: Pelvic radiotherapy
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic radiotherapy (50Gy prescription dose)
Study: 32534807
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate with leucovorin rescue (HDMTX-LR)
Study: 35102967
Drug: 4% articaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% articaine buccal infiltration
Study: 36149216
Drug: Standard Triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Triple Therapy (sTT)
Study: 36149216
Drug: Bismuth-Containing Quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-Containing Quadruple Therapy (BQT)
Study: 36149216
Drug: Hybrid Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid Therapy (HT)
Study: 34161952
Drug: Bio-enhanced turmeric
Normalized name: Turmeric
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio-enhanced turmeric formulation (BTF) 1 g/day
Study: 34161952
Drug: Bio-enhanced turmeric
Normalized name: Turmeric
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio-enhanced turmeric formulation (BTF) 1.5 g/day
Study: 34161952
Drug: Bio-enhanced turmeric
Normalized name: Turmeric
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio-enhanced turmeric formulation (BTF)
Study: 32684633
Drug: Bortezomib-containing induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib-containing induction therapy (IT), high-dose melphalan (MEL200), autologous blood stem cell transplantation (ASCT), consolidation, and maintenance with lenalidomide
Study: 34278044
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (750 mg)
Study: 39535683
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide
Study: 35381839
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg orally two hours before surgery and 24 hours after surgery
Study: 33210787
Drug: Peri-implant diseases
Normalized name: PAD,PERI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peri-implant diseases
Study: 39010171
Drug: Saline nasal
Normalized name: Ayr Saline Nasal
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline nasal spray (Control)
Study: 35979901
Drug: 15-mL oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-mL oral solution of aspirin (300 mg)
Study: 35979901
Drug: Chewed aspirin
Normalized name: aspirin Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewed aspirin tablet (300 mg)
Study: 33986063
Drug: Cream cracker
Normalized name: crack willow pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream cracker
Study: 33742282
Drug: Control playgroup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control playgroup (following cognitive-behavioral therapy for PND)
Study: 35170885
Drug: Prayer (reciting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prayer (reciting for 10 minutes three times daily)
Study: 35170885
Drug: Ginger (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (250 mg capsules plus 20 ml water after each meal)
Study: 35170885
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo starch capsules, 250 mg daily)
Study: 32366241
Drug: Rectal STI
Normalized name: STI-1499
DrugBank: STI-1499 (DB16487)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal STI test selection
Study: 34698704
Drug: Infant Mental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant Mental Health Home Visiting (IMH‐HV) treatment
Study: 33682353
Drug: Biologic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic therapy (a biologic disease-modifying antirheumatic drug plus methotrexate)
Study: 33682353
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (methotrexate plus sulfasalazine plus hydroxychloroquine/chloroquine)
Study: 34440974
Drug: Virtual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual therapy (VR) in an eight-week cardiac rehabilitation program
Study: 35307850
Drug: P22-TAB (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: P22-TAB (250 mg)
Study: 35307850
Drug: P22-CAP (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: P22-CAP (250 mg)
Study: 35307850
Drug: P01-CAP (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: P01-CAP (250 mg)
Study: 34890377
Drug: 10 days
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days antibiotic therapy (SDR group)
Study: 34890377
Drug: 14 days
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14 days antibiotic therapy (LDR group)
Study: 33635894
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment for two weeks
Study: 34925204
Drug: Transcranial direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial direct current stimulation (tDCS) combined with conventional, individualised rehabilitation therapy.
Study: 34925204
Drug: Conventional, individualised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional, individualised rehabilitation therapy (Control group).
Study: 33891570
Drug: Acupressure on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupressure on three acupuncture points (LI4, SP6, ST36) for three minutes twice daily for four weeks
Study: 33618735
Drug: Existing preschool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Existing preschool oral healthcare programme (POHP)
Study: 33308257
Drug: TB treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TB treatment adherence intervention (educational outreach, point-of-care reminder tool, peer support network)
Study: 35971596
Drug: AZD9977 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9977 100 mg once daily for 14 days, up-titrated to 200 mg for another 14 days
Study: 35971596
Drug: Spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg once daily for 14 days, up-titrated to 50 mg for another 14 days
Study: 34886680
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg once daily
Study: 32272243
Drug: Budesonide Oral
Normalized name: budesonide Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide Oral Suspension (BOS) 2.0 mg twice daily for 12 weeks
Study: 35692186
Drug: Tetrahydrocannabinol (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrahydrocannabinol (dose = 13‐49 mg)
Study: 36713761
Drug: Rivaroxaban monotherapy
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban monotherapy
Study: 35704345
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with rivaroxaban and antiplatelet therapy
Study: 33279874
Drug: Erlotinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib plus bevacizumab (15 mg/kg every 21 days)
Study: 33279874
Drug: Erlotinib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib monotherapy (150 mg once daily)
Study: 36054477
Drug: Preoperative NSAIDs
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative NSAIDs (administered from 24 hours pre-surgery to day 7 post-surgery)
Study: 36054477
Drug: Postoperative NSAIDs
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative NSAIDs (administered from 12 hours post-surgery to day 7 post-surgery)
Study: 35710394
Drug: Inpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient treatment as usual
Study: 35710394
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Stepped care day patient approach and Inpatient treatment as usual)
Study: 33223005
Drug: 0.75 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg.kg‐1 flurbiprofen axetil (Group C)
Study: 33223005
Drug: 1 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg.kg‐1 flurbiprofen axetil (Group D)
Study: 33223005
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of Intralipid (Group A, control group)
Study: 33223005
Drug: 0.5 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg.kg‐1 flurbiprofen axetil (Group B)
Study: 32141787
Drug: IncobotulinumtoxinA 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: IncobotulinumtoxinA 400 U injection in J-PURE (upper limb)
Study: 32141787
Drug: IncobotulinumtoxinA 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: IncobotulinumtoxinA 400 U injection in J-PLUS (lower limb)
Study: 35229691
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma added to conventional therapy
Study: 32241351
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) applied every 4 weeks for 12 weeks
Study: 34036828
Drug: Systematic visual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic visual oral examinations for screening
Study: 34036828
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of primary health care workers for oral cancer screening
Study: 32470370
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg Diclofenac Potassium (DFK)
Study: 32248163
Drug: Common treatment
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common treatment scheme (control group)
Study: 32551724
Drug: Both therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both therapies (DET and CPT)
Study: 33926539
Drug: Radiofrequency ablation
Normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency ablation (RFA) followed by chemotherapy
Study: 34460897
Drug: 12-week outpatient
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week outpatient physical therapy program with progressive resistance training (PRT)
Study: 34460897
Drug: 6-week outpatient
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6-week outpatient physical therapy program with progressive resistance training (PRT)
Study: 32532789
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg once every 2 weeks until disease progression or unacceptable toxicity
Study: 32131366
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A received a sachet containing 5 g CPs, 3.6 g calcium lactate (equivalent to 500 mg of elemental calcium) and 400 IU vitamin D3
Study: 32131366
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B received a chewable tablet containing 1.25 g calcium carbonate (equivalent to 500 mg of elemental calcium) and 400 IU vitamin D3 daily
Study: 32764898
Drug: FNB (femoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: FNB (femoral nerve block) with 15 mL of 0.5% ropivacaine
Study: 32764898
Drug: FICB (fascia
Approvals — FDA: no, EMA: no, PMDA: no
Description: FICB (fascia iliaca compartment block) with 40 mL of 0.5% ropivacaine
Study: 36385193
Drug: Calcifediol (HyD,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcifediol (HyD, 20 mcg/d)
Study: 33433351
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of perindopril tert-butylamine tablets (4 mg)
Study: 34263280
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of daidzein with 10 g soy protein
Study: 34263280
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of genistein with 10 g soy protein
Study: 34263280
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg of daidzein and genistein with 10 g soy protein (placebo group)
Study: 35247994
Drug: Standard oncological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oncological treatments (checkpoint inhibitors, checkpoint inhibitors combined with chemotherapy or oncological surveillance)
Study: 33625743
Drug: Biodegradable implants
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biodegradable implants
Study: 32666354
Drug: Desvenlafaxine succinate
Normalized name: Desvenlafaxine Succinate
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desvenlafaxine succinate monohydrate extended release tablets
Study: 32666354
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro dissolution tests using USP apparatus 1 at 75 rpm with HCl pH 1.2, acetate buffer solution pH 4.5, or phosphate buffer solution pH 6.8
Study: 34406788
Drug: Conidial suspension
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conidial suspension (1 × 10^6 conidia/ml) inoculation on three leaves of three plants
Study: 32794449
Drug: Online imaginal
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Online imaginal exposure therapy for EDs (4 sessions over 4 weeks)
Study: 35851045
Drug: Budesonide/formoterol 200/6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol 200/6 μg via turbuhaler
Study: 35851045
Drug: Salbutamol 100
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol 100 μg via MDI
Study: 36137682
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (vitamin K antagonists or antiplatelet therapy)
Study: 36137682
Drug: Apixaban vs
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban vs antiplatelet therapy
Study: 36137682
Drug: Apixaban vs
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban vs vitamin K antagonists